Skip to main content
SpringerLink
Log in

Paraneoplastic neurologic syndromes

  • Chapter
The Teaching Cases from Annals of Oncology

  • 92 Accesses

Abstract

Paraneoplastic neurologic syndromes (PNS) are remote, nonmetastatic complications of systemic cancer. Clinically they are characterized by subacute, progressive neurologic deficits that usually result in profound disability and eventually death. PNS may be present as long as 2 to 4 years before diagnosis of the associated tumor, but it can develop after diagnosis or when the cancer is thought to be in remission. Serum and cere-brospinal fluid (CSF) from many patients with PNS contains antineuronal antibodies which recognise antigens within the tumor. This suggests that PNS are autoimmune disorders in which the immune response, elicited by the patient’s tumor, cross-reacts with specific neuronal proteins.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 16.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Bunn PA Jr., Ridgway EC. Paraneoplastic syndromes: Neurologic manifestation of malignancy. In DeVitta V, Hellmann S, Rosenberg SA (eds): Cancer, Principles and Practive of Oncology. Philadelphia: J.B. Lippincott Company 1993; 2026-71.

    Google Scholar 

  2. Greenlee JE, Brashear HR. Remote effects of carcinoma. In Johnson RT, Griffin JW (eds): Current Therapy on Neurologic Diseases. St. Louis, MO: Mosby Year Book Inc. 1993; 235–9.

    Google Scholar 

  3. Schuller-Petrovic S, Gebhart W, Lassmann H et al. A shared antigenic determinant between natural killer cells and nervous tissue. Nature 1983; 306:179–81.

    Article  CAS  PubMed  Google Scholar 

  4. Bunn PA, Gazdar AF, Carney DN et al. Small cell lung carcinoma and natural killer cells share an antigen determinant, Leu-7. Clin Res 1984; 32:413A.

    Google Scholar 

  5. Kimmel DW, O’Neill BP, Lennon VA. Subacute sensory neuronopathy associated with small cell lung carcinoma: Diagnosis aided by autoimmune serology. Mayo Clin Proc 1988; 63:29–32.

    Article  CAS  PubMed  Google Scholar 

  6. Dalmau J, Furneaux HM, Gralla RJ et al. Detection of the anti-Hu antibody in the serum of patients with small cell lung cancer — a quantitative Western blot analysis. Ann Neurol 1990; 27:544–52.

    Article  CAS  PubMed  Google Scholar 

  7. Dalmau J, Furneaux HM, Rosenblum MK er al. Detection of the anti-Hu antibody in specific regions of the nervous system and tumor from patients wih paraneoplastic encephalomyelitis/ sensory neuronopathy. Neurology 1991; 41:1757–64.

    Article  CAS  PubMed  Google Scholar 

  8. Posner JB. Pathogenesis of central nervous system paraneoplastic syndromes. Rev Neurol (Paris) 1992; 148:502–12.

    CAS  Google Scholar 

  9. Dropcho EJ, Chen YT, Posner JB et al. Cloning of a brain protein identified by autoantibodies from a patient with paraneoplastic cerebellar degeneration. PNAS 1987; 84:4552–6.

    Article  CAS  PubMed  Google Scholar 

  10. Sakai K, Mitchel DJ, Tsukamoto T et al. Isolation of a complementary DNA clone encoding an autoantigen recognized by an anti-neuronal cell antibody from a patient with paraneoplastic cerebellar degeneration. Ann Neurol 1990; 28:692–8.

    Article  CAS  PubMed  Google Scholar 

  11. Siniscalco M, Oberle I, Melis P et al. Physical and genetic mapping of the CDR gene with particular reference to its position with respect to the FRAXA site. Am J Med Genetics 1991; 38:357–62.

    Article  CAS  Google Scholar 

  12. Fatallah-Shaykh H, Wolf S, Wong E et al. Cloning of a leucinezipper protein recognized by the sera of patients with antibody-associated paraneoplastic cerebellar degeneration. PNAS 1991; 88:3451–4.

    Article  Google Scholar 

  13. Wilkinson PC, Zeromsky J. Immunofluorescent detection of antibodies against neurons in sensory carcinomatous neuropathy. Brain 1965; 88:529–38.

    Article  CAS  PubMed  Google Scholar 

  14. Luque AF, Furneaux HM, Fergizer R et al. Anti-Ri: An antibody associated with paraneoplastic opsoclonus and breast cancer. Ann Neurol 1991; 29:241–51.

    Article  CAS  PubMed  Google Scholar 

  15. Darnell RB, Posner JB. Cloning and characterization of the neuronal antigen recognized in paraneoplastic opsoclonus-myoclonus. Neurology 1991; 41 (Supp11):363.

    Article  Google Scholar 

  16. Jacobson DM, Thirkill CE, Tipping SJ. A clinical triad to diagnose paraneoplastic retinopathy. Ann Neurol 1990; 28:162–7.

    Article  CAS  PubMed  Google Scholar 

  17. Anderson HJ, Churchill-Davidson HC, Richardson AT. Bronchial neoplasm with myasthenia: Prolonged apnoea after administration of succinylcholine. Lancet 1953; 2:1291–3.

    Article  Google Scholar 

  18. O’Neill JH, Murray NMF, Newsom-Davis J. The Lambert-Eaton myasthenic syndrome. A review of 50 cases. Brain 1988; 111:577–96.

    Article  Google Scholar 

  19. Bromberg MB, Albers JW, McCune WJ. Transient Lambert-Easton myasthenic syndrome associated with systemic lupus erythematosus. Muscle Nerve 1989; 12:15–9.

    Article  CAS  PubMed  Google Scholar 

  20. Newsom-Davis J, Leys K, Vincent A et al. Immunological evidence for the co-existence of the Lambert-Eaton myasthenic syndrome and myasthenia gravis in two patients. J Neurol Neurosurg Psychiatry 1991; 54:452–3.

    Article  CAS  PubMed  Google Scholar 

  21. Eaton LM, Lambert EH. Electromyography and electric stimulation of nerves in diseases of motor unit: Observations on myasthenic syndrome associated with malignant tumors. JAMA 1957; 163:1117–24.

    Article  CAS  Google Scholar 

  22. Kim Yl. Passively transferred Lambert-Easton syndrome in mice receiving purified IgG. Muscle Nerve 1986; 9:523–30.

    Article  CAS  PubMed  Google Scholar 

  23. Lang B, Newsom-Davis J, Wray D et al. Autoimmune aetiology for myasthenic Lambert-Eaton syndrome. Lancet 1981; 2:224–6.

    Article  CAS  PubMed  Google Scholar 

  24. Newsom-Davis J, Murray NM. Plasma exchange and immunosuppressive drug treatment in the Lambert-Easton myasthenic syndrome. Neurology 1984; 34:480–5.

    Article  CAS  PubMed  Google Scholar 

  25. Kim Yl, Neher E. IgG from patients with Lambert-Eaton syndrome blocks voltage-dependant calcium channels. Science 1988; 239:405–8.

    Article  CAS  PubMed  Google Scholar 

  26. Fukuoka T, Engel AG, Lang B et al. Lambert-Eaton myasthenic syndrome II. Immunoelectron microscopy localization of IgG at the mouse motor end-plate. Ann Neurol 1987; 22:200–11.

    Article  CAS  PubMed  Google Scholar 

  27. Nagel A, Engel AG, Lang B. Lambert-Eaton myasthenic syndrome IgG depletes presynaptic membrane active zone particles by antigenic modulation. Ann Neurol 1988; 24:552–8.

    Article  CAS  PubMed  Google Scholar 

  28. Lennon VA, Lambert EH. Autoantibodies bind solubilized calcium channel-ω-conotoxin complexes from small cell lung carcinoma. A diagnostic aid for the Lambert-Eaton myasthenic syndrome. Mayo Clin Proc 1989; 64:1498–504.

    Article  CAS  PubMed  Google Scholar 

  29. Sher E, Gotti C, Canal N et al. Specificity of calcium channel autoantibodies in Lambert-Eaton myasthenic syndrome. Lancet 1989; 2:640–3.

    Article  CAS  PubMed  Google Scholar 

  30. Leys K, Lang B, Johnston I et al. Calcium channel autoantibodies in the Lambert-Eaton myasthenic syndrome. Ann Neuro 1991; 29:307–14.

    Article  CAS  Google Scholar 

  31. Bird SJ. Clinical and electrophysiologic improvement in Lambert-Eaton syndrome with intravenous immunoglobulin therapy. Neurology 1992; 42:1422–3.

    Article  CAS  PubMed  Google Scholar 

  32. McEvoy KM. Lambert-Eaton myasthenic syndrome. InJohnson RT, Griffin JW (eds): Current Therapy on Neurologic disease. St. Louis, MO: Mosby Year Book Inc. 1993; 384–8.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Centre Pluridisciplinaire d’Oncologie, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland

    J. Bauer & S. Leyvraz

  2. Neurology Department, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland

    T. Kuntzer

Authors
  1. J. Bauer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. T. Kuntzer
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. S. Leyvraz
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Oncology, University College London Medical School, The Middlesex Hospital, London, UK

    R. L. Souhami

Rights and permissions

Reprints and permissions

Copyright information

© 1997 Springer Science+Business Media Dordrecht

About this chapter

Cite this chapter

Bauer, J., Kuntzer, T., Leyvraz, S. (1997). Paraneoplastic neurologic syndromes. In: Souhami, R.L. (eds) The Teaching Cases from Annals of Oncology. Springer, Dordrecht. https://doi.org/10.1007/978-94-011-5456-7_5

Download citation

  • DOI: https://doi.org/10.1007/978-94-011-5456-7_5

  • Publisher Name: Springer, Dordrecht

  • Print ISBN: 978-0-7923-4117-8

  • Online ISBN: 978-94-011-5456-7

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation